Ascelia Pharma AB (publ) (ticker: ACE) a biotech focused on improving the life of people living with rare cancer conditions, today announced that it has expanded its leadership team to include all line functions that report directly to CEO Magnus Corfitzen. The company’s Chief Medical Officer (CMO) Carl Bjartmar has decided to retire by the end of 2022.
Ascelia Pharma’s new leadership team will consist of the following seven members:
- Magnus Corfitzen, CEO
- Julie Waras Brogren, Deputy CEO & CCO
- Déspina Georgiadou Hedin, CFO
- Andreas Norlin, CSO
- Carin Linde, VP Product Development & Supply and IT
- Marie Källström, VP Regulatory Affairs and QA
- VP Clinical Development (Joins the company in November)
“The expansion of our leadership team is important to prepare for the expected growth ahead of us as we will be moving towards becoming a commercial stage company. I am delighted to announce the promotions of Julie to Deputy CEO, Andreas to CSO and Marie to VP and individually as well as collectively we have a strong leadership team to bring Ascelia Pharma successfully forward,” said Magnus Corfitzen, CEO of Ascelia Pharma.
Ascelia Pharma’s CMO, Dr Carl Bjartmar has decided to retire by the end of the year.
“I want to thank Carl for his invaluable contributions to Ascelia Pharma over these years and wish him all the best”, said Magnus Corfitzen.